In conclusion, this analysis revealed that FMO2 was lower expressed in breast cancer compared with normal tissues and contributes to subtype classification and prognosis prediction with co-expressed SFRP1, which could be considered as a predictive biomarker for breast cancer treatment indecently of the Wnt signal pathway by affecting the extracellular matrix. Here, SFRP1 is linked to breast carcinoma.